See more : Current Water Technologies Inc. (ENPRF) Income Statement Analysis – Financial Results
Complete financial analysis of Enzo Biochem, Inc. (ENZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enzo Biochem, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Allcargo Terminals Limited (ATL.NS) Income Statement Analysis – Financial Results
- Moovly Media Inc. (MVVYF) Income Statement Analysis – Financial Results
- RCI Hospitality Holdings, Inc. (0KT6.L) Income Statement Analysis – Financial Results
- Central Bancompany, Inc. (CBCY) Income Statement Analysis – Financial Results
- IHI Corporation (IHICY) Income Statement Analysis – Financial Results
Enzo Biochem, Inc. (ENZ)
About Enzo Biochem, Inc.
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.91M | 31.06M | 107.07M | 117.73M | 76.02M | 81.17M | 104.71M | 107.80M | 102.77M | 97.60M | 95.95M | 93.71M | 103.08M | 102.03M | 97.08M | 89.57M | 77.80M | 52.91M | 39.83M | 43.40M | 41.64M | 52.77M | 54.02M | 58.41M | 50.03M | 44.30M | 40.40M | 34.90M | 34.50M | 31.70M | 22.80M | 20.00M | 20.50M | 19.80M | 19.40M | 12.10M | 9.10M | 8.70M | 7.30M |
| Cost of Revenue | 17.28M | 19.50M | 65.10M | 64.15M | 52.25M | 57.92M | 60.39M | 59.48M | 57.19M | 54.77M | 54.27M | 54.84M | 55.97M | 53.82M | 52.12M | 53.06M | 40.22M | 23.23M | 16.09M | 14.74M | 13.10M | 11.78M | 10.85M | 17.42M | 14.10M | 14.30M | 13.80M | 13.80M | 13.60M | 12.10M | 9.30M | 6.70M | 6.20M | 21.20M | 5.20M | 3.60M | 1.90M | 1.70M | 1.40M |
| Gross Profit | 14.63M | 11.57M | 41.97M | 53.58M | 23.77M | 23.25M | 44.33M | 48.33M | 45.58M | 42.83M | 41.68M | 38.87M | 47.11M | 48.21M | 44.97M | 36.51M | 37.57M | 29.68M | 23.74M | 28.66M | 28.54M | 40.99M | 43.17M | 40.98M | 35.93M | 30.00M | 26.60M | 21.10M | 20.90M | 19.60M | 13.50M | 13.30M | 14.30M | -1.40M | 14.20M | 8.50M | 7.20M | 7.00M | 5.90M |
| Gross Profit Ratio | 45.86% | 37.24% | 39.20% | 45.51% | 31.27% | 28.64% | 42.33% | 44.83% | 44.35% | 43.88% | 43.44% | 41.48% | 45.70% | 47.25% | 46.32% | 40.76% | 48.30% | 56.09% | 59.60% | 66.03% | 68.53% | 77.67% | 79.92% | 70.17% | 71.81% | 67.72% | 65.84% | 60.46% | 60.58% | 61.83% | 59.21% | 66.50% | 69.76% | -7.07% | 73.20% | 70.25% | 79.12% | 80.46% | 80.82% |
| Research & Development | 2.64M | 3.90M | 3.77M | 3.25M | 4.45M | 3.18M | 3.21M | 2.93M | 3.52M | 3.35M | 3.14M | 3.89M | 6.29M | 7.81M | 9.70M | 9.22M | 8.64M | 9.39M | 7.90M | 8.45M | 8.08M | 8.31M | 6.18M | 6.08M | 5.43M | 4.40M | 4.00M | 3.60M | 3.10M | 2.40M | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 24.36M | 27.20M | 53.71M | 44.91M | 49.69M | 44.27M | 44.47M | 44.01M | 43.59M | 41.07M | 41.80M | 43.65M | 51.65M | 48.90M | 52.09M | 45.51M | 43.72M | 41.25M | 35.99M | 30.51M | 32.69M | 28.30M | 28.00M | 25.67M | 23.49M | 20.40M | 19.90M | 16.00M | 17.50M | 17.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -2.63M | 345.00K | 577.00K | 400.00K | 437.00K | 374.00K | 580.00K | 649.00K | 601.00K | 556.00K | 440.00K | 302.00K | 237.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.72M | 27.20M | 53.71M | 44.91M | 42.96M | 44.27M | 44.47M | 44.01M | 43.59M | 41.07M | 41.80M | 43.65M | 51.65M | 48.90M | 52.09M | 45.51M | 43.72M | 41.25M | 35.99M | 30.51M | 32.69M | 28.30M | 28.00M | 25.67M | 23.49M | 20.40M | 19.90M | 16.00M | 17.50M | 17.10M | 10.60M | 16.90M | 12.90M | 0.00 | 15.80M | 12.20M | 9.60M | 9.60M | 4.50M |
| Other Expenses | 0.00 | 380.00K | -1.19M | 6.91M | 488.00K | 382.00K | 168.00K | 125.00K | 122.00K | 95.00K | 194.00K | 5.00K | 5.10M | 4.43M | 3.48M | 5.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.93M | 1.90M | 1.90M | 1.80M | 1.80M | 1.80M | 1.50M | 1.50M | 700.00K | 1.20M | 500.00K | 300.00K | 0.00 | 500.00K | 300.00K |
| Operating Expenses | 27.00M | 31.11M | 57.47M | 48.16M | 47.41M | 47.44M | 51.37M | 49.71M | 49.45M | 46.70M | 48.01M | 52.04M | 63.05M | 61.14M | 65.28M | 60.57M | 52.36M | 50.64M | 43.89M | 38.96M | 40.77M | 36.61M | 34.18M | 31.75M | 30.84M | 26.70M | 25.80M | 21.40M | 22.40M | 21.30M | 13.90M | 18.40M | 13.60M | 1.20M | 16.30M | 12.50M | 10.10M | 10.10M | 4.80M |
| Cost & Expenses | 44.27M | 50.60M | 122.58M | 112.31M | 99.66M | 105.36M | 111.75M | 109.19M | 106.64M | 101.48M | 102.27M | 106.87M | 119.02M | 114.96M | 117.39M | 113.63M | 92.58M | 73.87M | 59.98M | 53.71M | 53.88M | 48.40M | 45.03M | 49.18M | 44.94M | 41.00M | 39.60M | 35.20M | 36.00M | 33.40M | 23.20M | 25.10M | 19.80M | 22.40M | 21.50M | 16.10M | 12.00M | 11.80M | 6.20M |
| Interest Income | 3.54M | 0.00 | 178.00K | 8.00K | 454.00K | 1.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 581.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 197.00K | 0.00 | 159.00K | 0.00 | 0.00 | 0.00 | 9.78M | 2.58M | 0.00 | 0.00 | 7.14M | 11.52M | 49.99M | 0.00 | 3.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.00M | 0.00 | 0.00 | 2.70M | 1.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.27M | 2.68M | 2.83M | 2.65M | 2.78M | 3.04M | 3.13M | 3.60M | 3.84M | 3.79M | 3.97M | 4.61M | 4.48M | 4.47M | 4.27M | 3.46M | 2.15M | 1.19M | 1.12M | 2.33M | 2.36M | 1.81M | 2.15M | 2.25M | 1.93M | 1.90M | 1.90M | 1.80M | 1.80M | 1.80M | 1.50M | 1.50M | 700.00K | 1.20M | 500.00K | 300.00K | 500.00K | 500.00K | 300.00K |
| EBITDA | -8.35M | -20.94M | -15.01M | 3.35M | -27.59M | -24.16M | -3.91M | 1.09M | -6.56M | -1.21M | -5.73M | -14.29M | -11.46M | -8.35M | -17.99M | -20.02M | -8.75M | -19.78M | -19.03M | -7.97M | -9.87M | 6.18M | 11.14M | 11.48M | 7.01M | 5.20M | 2.70M | 1.50M | 300.00K | 100.00K | 1.10M | -3.60M | 1.40M | -1.40M | -1.60M | -3.70M | -2.40M | -2.60M | 1.40M |
| EBITDA Ratio | -26.16% | -39.01% | -10.23% | 10.64% | -19.78% | 100.00% | 100.00% | 100.00% | 100.00% | -1.87% | 1.26% | -3.02% | 13.14% | -8.38% | -14.50% | -22.99% | -16.50% | -42.48% | -47.78% | -50.63% | -23.70% | 11.71% | 20.63% | 19.66% | 14.01% | 11.74% | 1.98% | -0.86% | 18.26% | -35.65% | -6.14% | -13.00% | 8.78% | 16.67% | -19.59% | -61.16% | -59.34% | -67.82% | -9.59% |
| Operating Income | -9.82M | -24.74M | -15.51M | 9.88M | -23.64M | 78.13M | -12.16M | -3.07M | 47.00M | -1.21M | -10.18M | -18.98M | -40.48M | -12.93M | -22.06M | -24.06M | -14.79M | -20.97M | -20.15M | -10.31M | -12.23M | 4.37M | 8.99M | 9.23M | 5.08M | 3.30M | 800.00K | -300.00K | -1.50M | -1.70M | -400.00K | -5.10M | 700.00K | -2.60M | -2.10M | -4.00M | -2.90M | -3.10M | 1.10M |
| Operating Income Ratio | -30.77% | -79.64% | -14.48% | 8.39% | -31.09% | 96.26% | -11.62% | -2.84% | 45.73% | -1.24% | -10.61% | -20.25% | -39.27% | -12.67% | -22.72% | -26.86% | -19.01% | -39.63% | -50.60% | -23.74% | -29.37% | 8.28% | 16.64% | 15.80% | 10.16% | 7.45% | 1.98% | -0.86% | -4.35% | -5.36% | -1.75% | -25.50% | 3.41% | -13.13% | -10.82% | -33.06% | -31.87% | -35.63% | 15.07% |
| Total Other Income/Expenses | 0.00 | -286.00K | -3.31M | 7.18M | 1.85M | 29.68M | 746.00K | 644.00K | 56.92M | -1.09M | 275.00K | 31.00K | -442.00K | 105.00K | -203.00K | -70.00K | 3.89M | 7.79M | 3.14M | 15.52M | 1.15M | 1.36M | 1.35M | 3.00M | 2.58M | 2.10M | 1.80M | 1.90M | -6.00M | 11.40M | 2.60M | -1.20M | -1.80M | 2.60M | -1.80M | 0.00 | 3.00M | -500.00K | 1.00M |
| Income Before Tax | -9.82M | -25.02M | -18.26M | 7.88M | -28.52M | 2.49M | -11.42M | -2.42M | 46.52M | -2.29M | -9.91M | -18.95M | -40.92M | -12.82M | -22.26M | -23.48M | -10.89M | -13.18M | -17.01M | 5.22M | -11.08M | 5.73M | 10.34M | 12.23M | 7.67M | 5.40M | 2.60M | 1.60M | -7.50M | 9.70M | 2.20M | -6.30M | -1.10M | -2.60M | -3.90M | -4.00M | 100.00K | -3.60M | 2.10M |
| Income Before Tax Ratio | -30.77% | -80.56% | -17.06% | 6.69% | -37.52% | 3.07% | -10.90% | -2.25% | 45.26% | -2.35% | -10.32% | -20.22% | -39.70% | -12.57% | -22.93% | -26.21% | -14.00% | -24.90% | -42.71% | 12.02% | -26.61% | 10.85% | 19.14% | 20.94% | 15.33% | 12.19% | 6.44% | 4.58% | -21.74% | 30.60% | 9.65% | -31.50% | -5.37% | -13.13% | -20.10% | -33.06% | 1.10% | -41.38% | 28.77% |
| Income Tax Expense | 0.00 | 12.30M | 4.32M | 4.45M | 5.37M | 101.27M | -1.10M | 82.00K | 1.23M | -7.00K | 72.00K | -712.00K | -1.65M | 137.00K | -28.00K | -87.00K | -239.00K | 85.00K | -1.34M | 2.21M | -4.85M | 1.88M | 3.42M | 5.42M | 1.04M | -1.10M | -800.00K | 100.00K | 200.00K | 4.10M | -2.90M | 100.00K | 100.00K | 12.90M | 200.00K | 100.00K | 600.00K | -2.00M | 600.00K |
| Net Income | -26.08M | 20.29M | -22.58M | 3.43M | -33.89M | -98.78M | -10.32M | -2.50M | 45.29M | -2.29M | -9.98M | -18.24M | -39.27M | -12.96M | -22.23M | -23.56M | -10.65M | -13.26M | -15.67M | 3.00M | -6.23M | 3.84M | 6.92M | 6.81M | 6.62M | 6.50M | 3.40M | 1.50M | -7.70M | 5.60M | 5.30M | -6.90M | -600.00K | -10.80M | -4.10M | -4.10M | -3.50M | -1.60M | 1.50M |
| Net Income Ratio | -81.73% | 65.32% | -21.09% | 2.91% | -44.58% | -121.70% | -9.86% | -2.32% | 44.06% | -2.34% | -10.40% | -19.46% | -38.09% | -12.70% | -22.90% | -26.31% | -13.69% | -25.06% | -39.34% | 6.92% | -14.96% | 7.28% | 12.82% | 11.66% | 13.24% | 14.67% | 8.42% | 4.30% | -22.32% | 17.67% | 23.25% | -34.50% | -2.93% | -54.55% | -21.13% | -33.88% | -38.46% | -18.39% | 20.55% |
| EPS | -0.51 | -1.27 | -0.46 | 0.07 | -0.71 | -2.09 | -0.22 | -0.05 | 0.98 | -0.05 | -0.23 | -0.46 | -1.01 | -0.34 | -0.59 | -0.63 | -0.29 | -0.38 | -0.49 | 0.09 | -0.20 | 0.11 | 0.22 | 0.22 | 0.22 | 0.21 | 0.12 | 0.05 | -0.27 | 0.19 | 0.19 | -0.29 | -0.03 | -0.71 | -0.26 | -0.27 | -0.24 | -0.11 | 0.09 |
| EPS Diluted | -0.51 | -1.27 | -0.46 | 0.07 | -0.71 | -2.08 | -0.22 | -0.05 | 0.97 | -0.05 | -0.23 | -0.46 | -1.01 | -0.34 | -0.59 | -0.63 | -0.29 | -0.38 | -0.49 | 0.09 | -0.20 | 0.11 | 0.22 | 0.21 | 0.20 | 0.21 | 0.11 | 0.05 | -0.27 | 0.19 | 0.18 | -0.29 | -0.03 | -0.71 | -0.26 | -0.27 | -0.24 | -0.11 | 0.09 |
| Weighted Avg Shares Out | 50.90M | 49.16M | 48.59M | 48.19M | 47.70M | 47.35M | 46.91M | 46.35M | 46.15M | 45.36M | 42.56M | 39.61M | 38.80M | 38.36M | 38.00M | 37.51M | 36.88M | 35.02M | 32.22M | 32.10M | 31.70M | 32.97M | 31.36M | 31.25M | 30.79M | 30.31M | 29.97M | 29.47M | 28.84M | 29.38M | 28.05M | 24.00M | 18.26M | 15.29M | 15.60M | 15.13M | 14.69M | 14.98M | 16.60M |
| Weighted Avg Shares Out (Dil) | 50.90M | 49.16M | 48.59M | 48.33M | 47.70M | 47.48M | 46.97M | 46.35M | 46.60M | 45.36M | 42.56M | 39.61M | 38.80M | 38.36M | 38.00M | 37.51M | 36.88M | 35.02M | 32.22M | 32.76M | 31.70M | 33.78M | 32.33M | 32.56M | 32.80M | 30.97M | 31.29M | 29.47M | 28.91M | 29.38M | 29.33M | 24.00M | 18.26M | 15.29M | 15.60M | 15.13M | 14.69M | 14.98M | 16.60M |
Steven J. Pully Appointed to Enzo Biochem's Board of Directors
FARMINGDALE, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading life sciences company, announced today that Steven J. Pully has been appointed to the Company's Board of Directors effective October 26, 2023....
Enzo Biochem: Cleaned Up And Cash-Rich But Unloved
Enzo Biochem is a microcap company with a $30 million revenue run-rate Life Sciences business and $78-$85 million in cash. The company is likely being prepared for sale, with interest from potential acquirers and activists controlling 30% of voting shares....
Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO
FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with...
Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp
Significant value unlocked for Enzo shareholders with continued focus on life sciences. FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo's Clinical laboratory...
Enzo Biochem Reports Third Quarter Fiscal Year 2023 Financial Results
- Enzo Life Sciences reports revenue of $7.5 million, with margin improvement in Q3 FY23 FARMINGDALE, NY, June 14, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, today filed its Form 10-Q for the third...
Federman & Sherwood Investigates Enzo Biochem for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #DataBreach--The law firm of Federman & Sherwood has initiated an investigation into Enzo Biochem with respect to their recent data breach. On May 30, 2023, Enzo Biochem notified 2.47 million patients that the company experienced a data...
Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale
FARMINGDALE, NY, May 22, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), announced today that the preliminary voting results from the Inspector of Election at today's Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by...
SHAREHOLDER ALERT: Weiss Law Investigates Enzo Biochem, Inc.
NEW YORK , May 2, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Enzo Biochem, Inc. ("Enzo Biochem" or the "Company") (NYSE: ENZ) in connection with...
Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders
FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo Biochem” or the “Company”), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the “Special Meeting”) to consider and vote on...
Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results
- Company entered into an Asset Purchase Agreement for substantially all of the operating assets of the Clinical Labs division
Source: https://incomestatements.info
Category: Stock Reports